Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
Bone Marrow Transplantation|March 27, 2023
Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapyIbrahim Yakoub-Agha, Raffaella Greco, Francesco Onida, et al.
Transfusion|June 27, 2014
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxideCurly Morris, Liesbeth de Wreede, Marijke Scholten, et al.
Haematologica|November 12, 2009
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO studyEmilio Paolo Alessandrino, Matteo Giovanni Della Porta, Andrea Bacigalupo, et al.
Bone Marrow Transplantation|April 9, 2025
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines CommitteeGuillermo Ortí, Guillaume Dachy, Charlotte E Graham, et al.
Journal of Crohn'S & Colitis|May 23, 2018
Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow TransplantationCharlotte K Brierley, Cristina Castilla-Llorente, Myriam Labopin, et al.
Expert Opinion on Biological Therapy|May 17, 2017
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Francesca Patriarca, Luisa Giaccone, Francesco Onida, et al.
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
American Journal of Hematology|April 23, 2013
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromeEmilio Paolo Alessandrino, Matteo G Della Porta, Luca Malcovati, et al.
Blood|February 22, 2014
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-RMatteo G Della Porta, Emilio Paolo Alessandrino, Andrea Bacigalupo, et al.
Leukemia & Lymphoma|January 7, 2016
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient programPier Luigi Zinzani, Cinzia Pellegrini, Giuseppe Cerciello, et al.
Pageof 14